메뉴 건너뛰기




Volumn 29, Issue 7, 2015, Pages 379-383

Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; EFAVIRENZ; ELVITEGRAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LEDIPASVIR; RALTEGRAVIR; RILPIVIRINE; SIMEPREVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR;

EID: 84934288281     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2015.0004     Document Type: Article
Times cited : (30)

References (41)
  • 1
    • 2642709177 scopus 로고    scopus 로고
    • Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
    • HIV Outpatient Study Investigators
    • Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
    • (1998) N Engl J Med , vol.338 , pp. 853-860
    • Palella, F.J.1    Delaney, K.M.2    Moorman, A.C.3
  • 2
    • 84874514203 scopus 로고    scopus 로고
    • Decreasing mortality and patterns of causes of death in the Swiss HIV Cohort Study
    • Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013;14:195-207.
    • (2013) HIV Med , vol.14 , pp. 195-207
    • Weber, R.1    Ruppik, M.2    Rickenbach, M.3
  • 3
    • 84872232623 scopus 로고    scopus 로고
    • Cause specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome negative individuals followed simultaneously in long-term cohort studies, 1984-2008
    • Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013;177:116-125.
    • (2013) Am J Epidemiol , vol.177 , pp. 116-125
    • Wada, N.1    Jacobson, L.P.2    Cohen, M.3    French, A.4    Phair, J.5    Munoz, A.6
  • 4
    • 70350457524 scopus 로고    scopus 로고
    • Human immunodeficiency virus in an aging population; A complication of success
    • Kirk J, Goetz MB. Human immunodeficiency virus in an aging population; A complication of success. J Am Geriatr Soc 2009;57:2129-2138.
    • (2009) J Am Geriatr Soc , vol.57 , pp. 2129-2138
    • Kirk, J.1    Goetz, M.B.2
  • 5
    • 84866379288 scopus 로고    scopus 로고
    • Allcause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV coinfection
    • Hernando V, Perez-Cachafeiro S, Lewden C, et al. Allcause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV coinfection. J Hepatol 2012;57:743-751.
    • (2012) J Hepatol , vol.57 , pp. 743-751
    • Hernando, V.1    Perez-Cachafeiro, S.2    Lewden, C.3
  • 6
    • 84921030343 scopus 로고    scopus 로고
    • Burden of HIV and hepatitis C co-infection: The changing epidemiology of hepatitis C in HIV-infected patients in France
    • Cacoub, P, Dabis F, Costagliola, D, et al. Burden of HIV and hepatitis C co-infection: The changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int 2015;35:65-70.
    • (2015) Liver Int , vol.35 , pp. 65-70
    • Cacoub, P.1    Dabis, F.2    Costagliola, D.3
  • 7
    • 34548709023 scopus 로고    scopus 로고
    • Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus infected patients undergoing highly active antiretroviral therapy
    • Pineda JA, García-García JA, Aguilar-Guisado M, et al; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus infected patients undergoing highly active antiretroviral therapy. Hepatology 2007;46:622-630.
    • (2007) Hepatology , vol.46 , pp. 622-630
    • Pineda, J.A.1    García-García, J.A.2    Aguilar-Guisado, M.3
  • 8
    • 17044412029 scopus 로고    scopus 로고
    • Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C
    • Buti M, San Miguel R, Brosa M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005;42:639-645.
    • (2005) J Hepatol , vol.42 , pp. 639-645
    • Buti, M.1    San Miguel, R.2    Brosa, M.3
  • 9
    • 85062055676 scopus 로고    scopus 로고
    • Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study
    • Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006;166:1632-1641.
    • (2006) Arch Intern Med , vol.166 , pp. 1632-1641
    • Weber, R.1    Sabin, C.A.2    Friis-Møller, N.3
  • 10
    • 34548057765 scopus 로고    scopus 로고
    • Hepatitis C in the HIV-infected patient
    • McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007;54:S47-S56.
    • (2007) J Acquir Immune Defic Syndr , vol.54 , pp. S47-S56
    • McGovern, B.H.1
  • 11
    • 84871487025 scopus 로고    scopus 로고
    • Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
    • Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
    • (2012) JAMA , vol.308 , pp. 2584-2593
    • Van Der Meer, A.J.1    Veldt, B.J.2    Feld, J.J.3
  • 12
    • 0034619946 scopus 로고    scopus 로고
    • Peginterferon alfa-2a in patients with chronic hepatitis C
    • Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
    • (2000) N Engl J Med , vol.343 , pp. 1666-1672
    • Zeuzem, S.1    Feinman, S.V.2    Rasenack, J.3
  • 13
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
    • (2002) N Engl J Med , vol.347 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 14
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
    • Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
    • (2004) Ann Intern Med , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette, H.2    Morgan, T.R.3
  • 15
    • 80052058359 scopus 로고    scopus 로고
    • A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans
    • Butt AA, McGinnis K, Skanderson M, Justice AC. A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans. AIDS Res Hum Retroviruses 2011;27:973-979.
    • (2011) AIDS Res Hum Retroviruses , vol.27 , pp. 973-979
    • Butt, A.A.1    McGinnis, K.2    Skanderson, M.3    Justice, A.C.4
  • 17
    • 84911409020 scopus 로고    scopus 로고
    • Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomized study
    • Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomized study. Lancet 2014; 384:1756-1765.
    • (2014) Lancet , vol.384 , pp. 1756-1765
    • Lawitz, E.1    Sulkowski, M.S.2    Ghalib, R.3
  • 18
    • 84900339263 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
    • Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
    • (2014) N Engl J Med , vol.370 , pp. 1889-1898
    • Afdhal, N.1    Zeuzem, S.2    Kwo, P.3
  • 19
    • 84898669547 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
    • Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
    • (2014) N Engl J Med , vol.370 , pp. 1483-1493
    • Afdhal, N.1    Reddy, K.R.2    Nelson, D.R.3
  • 20
    • 84900326091 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
    • Kowdley KV, Gordon SC, Reddy KR. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
    • (2014) N Engl J Med , vol.370 , pp. 1879-1888
    • Kowdley, K.V.1    Gordon, S.C.2    Reddy, K.R.3
  • 21
    • 84896696368 scopus 로고    scopus 로고
    • Titusville, NJ: Janssen Products
    • Olysio [package insert]. Titusville, NJ: Janssen Products, 2013.
    • (2013) Olysio [package Insert]
  • 24
    • 84925614860 scopus 로고    scopus 로고
    • Foster City, CA: Gilead
    • Harvoni [package insert]. Foster City, CA: Gilead, 2014.
    • (2014) Harvoni [package Insert]
  • 26
    • 84903795463 scopus 로고    scopus 로고
    • The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis
    • Yehia BR, Schranz AJ, Umschied CA, Lo Re V. The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. PLoS One 2014;9:e101554.
    • (2014) PLoS One , vol.9
    • Yehia, B.R.1    Schranz, A.J.2    Umschied, C.A.3    Lo Re, V.4
  • 28
    • 84904506394 scopus 로고    scopus 로고
    • The hepatitis C cascade of care among HIV infected patients: A call to address ongoing barriers to care
    • Cachay ER, Hill L, Wyles D, et al. The hepatitis C cascade of care among HIV infected patients: A call to address ongoing barriers to care. PLoS One. 2014;9:e102883.
    • (2014) PLoS One , vol.9
    • Cachay, E.R.1    Hill, L.2    Wyles, D.3
  • 29
    • 84883419062 scopus 로고    scopus 로고
    • Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection
    • Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med 2013b;159:372.
    • (2013) Ann Intern Med , vol.159 , pp. 372
    • Chou, R.1    Wasson, N.2
  • 30
    • 75349088230 scopus 로고    scopus 로고
    • Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C
    • Castera L, Sebastiani G, Le BB, de L, V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010;52:191-198.
    • (2010) J Hepatol , vol.52 , pp. 191-198
    • Castera, L.1    Sebastiani, G.2    Le, B.B.3    De L, V.4    Couzigou, P.5    Alberti, A.6
  • 31
    • 84856575734 scopus 로고    scopus 로고
    • The University of Liverpool Available at: Last accessed August 29, 2014
    • HIV-Drug Interactions. The University of Liverpool. Available at: http://www.hiv-druginteractions.org (Last accessed August 29, 2014).
    • HIV-Drug Interactions
  • 32
    • 0036174438 scopus 로고    scopus 로고
    • Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors
    • Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-723.
    • (2002) Antimicrob Agents Chemother , vol.46 , pp. 716-723
    • Birkus, G.1    Hitchcock, M.J.2    Cihlar, T.3
  • 34
    • 84904991493 scopus 로고    scopus 로고
    • Available at: Last accessed March 12, 2015
    • EASL. Recommendations on Treatment of Hepatitis C 2014. Available at: http://easl.eu (Last accessed March 12, 2015).
    • (2014) Recommendations on Treatment of Hepatitis C
  • 35
    • 84934319243 scopus 로고    scopus 로고
    • Uxbridge, UK: Bristol-Myers Squibb
    • Daklinza [package insert]. Uxbridge, UK: Bristol-Myers Squibb, 2015.
    • (2015) Daklinza [package Insert]
  • 36
    • 84891825080 scopus 로고    scopus 로고
    • Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection
    • Karageorgopoulos D, El-Sherif O, Bhagani S, Khoo S. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis 2014;27:36-45.
    • (2014) Curr Opin Infect Dis , vol.27 , pp. 36-45
    • Karageorgopoulos, D.1    El-Sherif, O.2    Bhagani, S.3    Khoo, S.4
  • 40
    • 84908665918 scopus 로고    scopus 로고
    • Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding
    • Issur M, Gotte M. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding. Viruses 2014;6:4227-4241.
    • (2014) Viruses , vol.6 , pp. 4227-4241
    • Issur, M.1    Gotte, M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.